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Extensive extraspinal hyperostoses after long-term 
oral retinoid treatment in a patient with pityriasis 
rubra pilaris
Rens J. van Dooren-Greebe, MD, and Peter C, M. van de Kerkhof, MD, PhD 
N ijm eg en , The N etherlands
We describe a patient with severe pityriasis rubra pilaris in whom extensive extraspinal hy­
perostoses developed after 13 years of oral retinoid treatment. The most prominent abnor­
mality was a bridging exostosis between the left acetabulum and collum. X-ray examinations 
of the spine during retinoid therapy showed no abnormalities. During oral retinoid treatment, 
it is important to ask the patient on a regular basis about any skeletal pains or mobility re­
striction* Normal spinal x-ray results are no guarantee that a patient is free of hyperostoses. 
Discontinuation of acitretin therapy resulted in a severe exacerbation of the patient’s pityr­
iasis rubra pilaris after 2 weeks. The clinical response to administration of azathioprine was 
clearly inferior to that of acitretin. However, low-dose oral methotrexate therapy appeared 
to be a good alternative in this patient, with a clinical result comparable to acitretin and no 
side effects after 6 months of therapy. (J A m  A c a d  D e r m a t o l  1995;32:322-5.)
Pityriasis rubra pilaris (PRP) is characterized by 
follicular erythematous and hyperkeratotic papules 
typically distributed on the trunk and extensor sur­
faces of the extremities. Extensive erythema and 
scaling or erythroderma may occur, interspersed 
with sharply demarcated “islands” of normal skin. 
Keratoderma of the palms and soles is common; the 
hyperkeratosis often has a yellowish color.1'3
Griffiths4 classified PRP into two adult types 
(classic and atypical) and three juvenile types (clas­
sic, circumscribed, and atypical). The classic adult 
type accounts for more than 50% of cases.4 Satis­
factory results with oral retinoid therapy have been 
reported,1 '3>5'7 although not all patients benefit from 
such treatment. Juvenile forms of PRP tend to have 
a better response to retinoid treatment than adult 
forms of the disease.5,6 Skeletal abnormalities with 
changes similar to DISH  (diffuse idiopathic skele­
tal hyperostoses), extraskeletal ossification, prema­
ture epiphyseal closure, and osteoporosis have been
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reported as long-term side effects of oral retinoid 
therapy.8"14 These skeletal changes strongly resem­
ble those observed in hypervitaminosis A syn­
drome.15 According to most authors, the spine is the 
site of predilection for retinoid-induced hyperos­
toses.
We describe a patient with PRP and extensive 
extraspinal hyperostoses after long-term retinoid 
treatment.
CASE REPORT
A boy born in 1959 had severe classic juvenile PRP that 
first started at age 9 years and consisted of a persistent 
erythroderma (except for some small “islands” of normal 
skin), hyperkeratotic follicular papules, and diffuse pal- 
moplantar hyperkeratosis (Fig. 1, A),
Histologic examination showed a slightly acanthotic 
epidermis and diifuse and follicular hyperkeratosis and 
parakeratosis. There was follicular plugging and perifol­
licular parakeratosis. The papillary dermis showed a pre­
dominantly lymphocytic infiltrate.
Local therapy and UVB irradiation were ineffective. 
Oral retinoid treatment was started in 1977 and contin­
ued until January 1992 (retinoic acid, 25 to 50 mg/day 
from 1977 to 1979; etretinate, 50to 75 mg/day from 1979 
to 1987; acitretin, 35 to 50 mg/day after 1987). This reg­
imen resulted in marked clinical improvement (Fig. 1, B). 
Side effects were limited to cheilitis and some alopecia. 
Attempts to lower the dosage of oral retinoids to less than 
35 mg/day (0.3 m g/kg/day) were unsuccessful. Addi­
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Fig. 1, A, PRP before treatment with acitretin. B, After 6 months of treatment with acitre­
tin, 35 to 50 mg/day.
tional routine x-ray examinations of the spinal column 
showed no abnormalities.
In August 1990 the patient reported progressive pain 
and restricted mobility in his left hip. Radiographs 
showed extensive periostal hyperostoses of both hips and, 
to a lesser extent, of the shoulders. A bridging exostosis 
was present between the left acetabulum and collum (Fig. 
2). Successful surgery was performed on the left hip. Ac­
itretin treatment was discontinued after surgery and 
PUVA therapy was started. Two weeks later treatment 
with acitretin was restarted because of a severe exacerba­
tion. In January 1992 acitretin therapy was again discon­
tinued. Azathioprine therapy was introduced with an ini­
tial dosage of 50 mg/day and a maintenance dosage of 
200 mg/day. The clinical response was inferior to that of 
acitretin therapy, but treatment was continued for 10
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Fig. 2. Extensive periostal hyperostoses and bridging exostosis between the left acetabulum 
and collum after 13 years of oral retinoid treatment.
months. In October 1992, the erythroderma became 
more pronounced and the patient reported malaise, thirst, 
and chills. Azathioprine therapy was discontinued and a 
2-week course of prednisone (30 mg/day) was prescribed. 
Subsequently methotrexate (MTX) was given according 
to the divided schedule proposed by Weinstein and 
Frost.16 The dosage was gradually increased from 7.5 
mg/wk to 15 mg/wk. Laboratory investigations were 
performed according to the international MTX guide­
lines.17 In general, the response to treatment with M TX 
has been satisfactory and comparable with the response 
to acitretin therapy, After 6 months of therapy there have 
been no clinical or laboratory side effects.
DISCUSSION
M any  reports have appeared about retinoid- 
induced skeletal abnorm alities ,8' 14 b u t the true  inci­
dence and severity o f skeletal problems are not yet 
sufficiently established. A  m ajo r problem is the  dif­
ferentiation of retinoid-induced bone changes from 
those induced as a result of aging or unrelated dis­
eases. I t  is generally accepted th a t  retinoid-induced 
skeletal abnorm alities predom inantly  affect the spi­
nal column. Exclusively extraspinal abnormalities 
have been reported only occasionally.9,18,19
Further prospective and controlled studies of 
retinoid-induced skeletal abnormalities are neces­
sary before definitive guidelines for the  surveillance 
of patients before and during retinoid treatm ent can 
be established. C urrently  most authors advise pre­
treatm ent and annual radiographs of the lateral 
spine with additional views of symptomatic ar­
eas. l0’ 1 1>20*21 O thers recommend additional screen­
ing of the  pelvis, calcaneus, and long bones. 12,14 F i­
nally, there are some authors who do not recommend 
any routine screening b u t only obtain radiographs of 
symptomatic areas in addition to  radiographs of the 
spine (and calcaneus) before trea tm en t .22,23
A  complete response to  azathioprine therapy (50 
to  200 m g /d ay ) in four of five patients with wide­
spread P R P  was reported by H unter and Forbes.24 
Griffiths4 reported a satisfactory response in seven of 
eight patients. There are several reports on the effi­
cacy of M T X  in P R P  4) 25-27 Usually daily or weekly 
schedules were used in dosages similar to the psori-
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asis schedule. In their review of PRP, Cohen and 
Prystowsky1 stated that “although most patients 
with PRP respond to methotrexate, many relapse 
when therapy is discontinued; reinstitution of the 
drug usually results in rapid clinical improvement.” 
Griffiths4 was less optimistic; combining his own 
data with those in the literature, he reported that of 
44 patients treated with MTX only 17 showed any 
response.
Azathioprine therapy was not successful in our 
patient, but low-dose oral MTX therapy was com­
parable to acitretin in efficacy.
This article illustrates the problems in manage­
ment of patients with retinoid-induced skeletal ab­
normalities. Discontinuation of retinoid therapy is 
not always possible; if it cannot be discontinued, 
more hyperostoses are likely to develop. It is impor­
tant to be aware that normal results of spinal x-ray 
studies do not guarantee that a patient is free of hy­
perostoses. It is also important to ask about skeletal 
pains and mobility problems regularly during oral 
retinoid treatment, because patients do not usually 
connect these symptoms with retinoid treatment and 
therefore do not always indicate them spontane­
ously.
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